ODI Pharma AB (publ) (NGM:ODI)
Sweden · Delayed Price · Currency is SEK 2.260
-0.080 (-3.42%)
At close: Sep 3, 2026
ODI Pharma AB Balance Sheet
Financials in millions SEK. Fiscal year is July - June.
Millions SEK. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 3.39 | 1.48 | 2.64 | 6.49 | 7.36 |
Cash & Short-Term Investments | 3.39 | 1.48 | 2.64 | 6.49 | 7.36 |
Cash Growth | 128.28% | -43.87% | -59.28% | -11.76% | -49.69% |
Accounts Receivable | 0.18 | 0.12 | 8.07 | 0.13 | 0.11 |
Other Receivables | 0.86 | 1.38 | 0.91 | 0.68 | 0.99 |
Receivables | 1.04 | 1.49 | 8.98 | 0.81 | 1.09 |
Inventory | - | - | - | 0.81 | 1.43 |
Prepaid Expenses | 0.86 | 0.63 | 0.59 | 0.06 | - |
Other Current Assets | - | - | - | 0 | 0.6 |
Total Current Assets | 5.29 | 3.61 | 12.22 | 8.18 | 10.48 |
Property, Plant & Equipment | 0.01 | 0 | 0.01 | 0.01 | 0.01 |
Other Long-Term Assets | - | 1 | 0 | - | - |
Total Assets | 5.3 | 4.61 | 12.23 | 8.19 | 10.5 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 1.77 | 0.39 | 5 | 0.71 | 0.67 |
Accrued Expenses | 0.83 | 1.01 | 1.16 | 0.35 | - |
Current Income Taxes Payable | - | 0 | 0.09 | 0 | - |
Current Unearned Revenue | - | - | - | - | 0.55 |
Other Current Liabilities | 0.33 | 2.79 | 3.98 | 4.54 | 0.01 |
Total Current Liabilities | 2.93 | 4.19 | 10.23 | 5.61 | 1.24 |
Total Liabilities | 2.93 | 4.19 | 10.23 | 5.61 | 1.24 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 0.73 | 0.64 | 0.61 | 0.61 | 0.61 |
Additional Paid-In Capital | 27.08 | 25.96 | 21.84 | 21.84 | 21.84 |
Comprehensive Income & Other | -25.43 | -26.17 | -20.45 | -19.88 | -13.19 |
Shareholders' Equity | 2.38 | 0.42 | 2 | 2.57 | 9.26 |
Total Liabilities & Equity | 5.3 | 4.61 | 12.23 | 8.19 | 10.5 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Net Cash (Debt) | 3.39 | 1.48 | 2.64 | 6.49 | 7.36 |
Net Cash Growth | 128.28% | -43.87% | -59.28% | -11.76% | -49.69% |
Net Cash Per Share | 0.18 | 0.08 | 0.17 | 0.42 | 0.49 |
Filing Date Shares Outstanding | 18.33 | 18.33 | 15.22 | 15.22 | 15.22 |
Total Common Shares Outstanding | 18.33 | 18.33 | 15.22 | 15.22 | 15.22 |
Working Capital | 2.36 | -0.58 | 1.99 | 2.56 | 9.25 |
Book Value Per Share | 0.13 | 0.02 | 0.13 | 0.17 | 0.61 |
Tangible Book Value | 2.38 | 0.42 | 2 | 2.57 | 9.26 |
Tangible Book Value Per Share | 0.13 | 0.02 | 0.13 | 0.17 | 0.61 |
Machinery | - | 0.04 | 0.04 | 0.04 | 0.04 |